Behavior of MV140 vaccine to prevent recurrent urinary tract infections in patients with metabolic syndrome and smoking

Abstract

Introduction: This study analyzed patients with metabolic syndrome and smokers treated with MV140 vaccine to prevent recurrent UTI. Material and methods: 342 patients with recurrent UTI received MV140 vaccine between 2017 and 2020 in Barcelona, Spain. Variables analyzed: number of UTI at 3 and 6 months after MV140, age, gender, diabetes mellitus, body mass index, hypertension, total cholesterol, HDL-cholesterol, triglycerides and smoking. Patients were divided in Group 1: metabolic syndrome (2 or more variables), Group 2: no metabolic syndrome (less than 2 variables). On the other hand, patients were classified into smokers and non-smokers. Results: Mean age was 74, 82% were women. At the beginning, 88,9% had 3-5 UTI. Overall effectiveness with MV140 was 72.5% at 3 months and 56.2% at 6 months. Group 1 (36%) presented 0-1 UTI in 78.9% and 62.6% at 3 and 6 months. In Group 2 (64%) the results were 69% and 52.5%. Comparing both groups, no statistically significant differences were observed (p=0,25, p=0,26). Smokers had 77.4% and 61.3% at 3 and 6 months, and non-smokers had 69.3% and 52.7%. There were also no statistically significant differences (p = 0.5, p = 0.36). Group 1 and smoking (28,7%) had 82% at 3 months and 66.3% at 6 months. Group 2 and no smoking (71,3%) reached 60.3% and 52% at 3 and 6 months. There were no statistically significant differences between both groups. Conclusions: The overall efficacy of MV140 was high and safe, without side effects. Patients with metabolic syndrome and smokers may benefit from this treatment.

Considering the best study designs to evaluate healthcare interventions

“…

Regarding the study published by Ramirez-Sevilla et al (1) in your prestigious journal, we would like to make specific comments:Metabolic syndrome encompasses multiple diseases, such as visceral obesity, hypertension, hyperglycemia, hypertriglyceridemia, and low high-density lipoprotein cholesterol levels (HDL-C). Multiple epidemiologic studies and meta-analyses demonstrate the association between Lower urinary tract symptoms and metabolic syndrome, according to its pathogenesis: systemic inflammation and oxidative stress.(2) In consequence, metabolic syndrome and all its components are risk factors for developing urinary tract infections, and this is a vital population for having the intention to prevent this deleterious condition.

…”

“…Regarding the study published by Ramirez-Sevilla et al (1) in your prestigious journal, we would like to make specific comments:…”